the complete application. Each copy should be stapled securely (front and back if necessary) in the upper left-hand corner. All pages of the narrative (including charts, tables, maps, exhibits, etc.) must be sequentially numbered, beginning with page one. In order to facilitate handling, please do not use covers, binders or tabs. Do not include extraneous materials as attachments, such as agency promotion brochures, slides, tapes, film clips, minutes of meetings, survey instruments or articles of incorporation.

G. Paper Reduction Act of 1995 (P.L. 104–13)

The Uniform Project Description information collection within this announcement is approved under the Uniform Project Description (0970–0139), Expiration Date 10/31/2000.

Public reporting burden for this collection of information is estimated to average 10 hours per response, including the time for reviewing instructions, gathering and maintaining the data needed, and reviewing the collection of information.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

(Federal Catalog of Domestic Assistance Number 93.631 Developmental Disabilities—Projects of National Significance)

Dated: March 11, 1999.

Sue Swenson,

Commissioner, Administration on Developmental Disabilities.

[FR Doc. 99–6456 Filed 3–16–99; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Subcommittee of the Anti-Infective Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Subcommittee of the Anti-Infective Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on April 23, 1999, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Kennedy Grand Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Contact Person: Rhonda W. Stover, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–6767, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12530. Please call the Information Line for up-to-date information on this meeting.

Agenda: The subcommittee will discuss issues in the development and study of all therapies in children relative to the implementation of the agency's new legislative and regulatory efforts to ensure adequate labeling and proper pediatric use.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by April 16, 1999. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 16, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 10, 1999.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 99–6459 Filed 3–16–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Human Tissue Seminar

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA), Los Angeles District Office, in cooperation with the American Society for Quality-Food, Drug, and Cosmetic Division (ASQ–FDC) is announcing the following seminar: Human Tissue Seminar. The topic to be discussed is public health regulations and guidance for recovery, screening, testing, processing, storage, or distribution of human tissue intended for transplantation. This seminar is being held for tissue firms in Southern California and Arizona.

Date and Time: The seminar will be held on Thursday, April 8, 1999, 8 a.m. to 5 p.m. Return the registration form by Thursday, April 1, 1999.

Location: The seminar will be held at the Food and Drug Administration, Los Angeles District Office, 19900 MacArthur Blvd., suite 300, Irvine, CA 92612.

Contact: Jonetta I. Collins, Supervisory Consumer Safety Officer, Food and Drug Administration, 19900 MacArthur Blvd., suite 300, Irvine, CA 92612, 949–798–7780, FAX 949–798–7771, e-mail ''jcollins@ora.fda.gov'', or Ofelia U. Barretto, West Coast Program Chair, ASQ–FDC, 714–870–4471, FAX 714–879–2737.

Registration: Space is limited; therefore, preregistration and confirmation is required. Obtain registration forms from Ofelia U. Barretto, ASQ–FDC (see above). There is a $95 registration fee payable to ASQ–FDC (address above) for the seminar. The fee will cover actual expenses including refreshments, a boxed lunch, materials, and some speaker expenses. In addition, building parking is $8 per car to attend the seminar. Return your completed registration form to Ofelia U. Barretto by Thursday, April 1, 1999.

If you need special accommodations due to a disability, please contact Jonetta I. Collins at least 7 days in advance.

Dated: March 9, 1999.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 99–6395 Filed 3–16–99; 8:45 am]

BILLING CODE 4160–01–F'

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the